Search alternatives:
significant linear » significant clinical (Expand Search), significant level (Expand Search), significant gender (Expand Search)
linear decrease » linear increase (Expand Search)
level decrease » levels decreased (Expand Search), level increased (Expand Search), level disease (Expand Search)
Showing 81 - 100 results of 87,519 for search '(( significant ((level decrease) OR (levels increased)) ) OR ( significant linear decrease ))', query time: 1.52s Refine Results
  1. 81
    DENV infection significantly reduces intracellular acylcarnitine levels.

    DENV infection significantly reduces intracellular acylcarnitine levels. by Li Xu (108702)

    Published 2024
    Save to List
    Saved in:
  2. 82
    Level of IgG IHA over time and difference of respective levels compared to baseline.

    Level of IgG IHA over time and difference of respective levels compared to baseline. by Beate Grüner (301524)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  3. 83
    Decreasing <i>abi</i> RNA levels in NCs results in increased BC migration speed.

    Decreasing <i>abi</i> RNA levels in NCs results in increased BC migration speed. by Ester Molina López (16462735)

    Published 2023
    Save to List
    Saved in:
  4. 84
    <i>RB1</i> expression levels increase and Thymidylate synthase (<i>TS</i>) expression levels decrease upon G418 treatment in SW1783 cells.

    <i>RB1</i> expression levels increase and Thymidylate synthase (<i>TS</i>) expression levels decrease upon G418 treatment in SW1783 cells. by Mireia Palomar-Siles (16406921)

    Published 2023
    Save to List
    Saved in:
  5. 85
    Histogram of cladogram and linear discriminant analysis (LDA) score.

    Histogram of cladogram and linear discriminant analysis (LDA) score. by Nguyen Thi Hai (12700147)

    Published 2022
    Save to List
    Saved in:
  6. 86
    Increasing and decreasing temperature trends in <i>M</i>. <i>peregrina</i> habitats at 95% confidence level.

    Increasing and decreasing temperature trends in <i>M</i>. <i>peregrina</i> habitats at 95% confidence level. by Hossein Piri Sahragard (19226096)

    Published 2024
    Save to List
    Saved in:
  7. 87
    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  8. 88
    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  9. 89
    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  10. 90
    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  11. 91
    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  12. 92
    Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  13. 93
    Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  14. 94
    Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  15. 95
    Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phas... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  16. 96
    Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interven... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  17. 97
    Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional pe... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  18. 98
    Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  19. 99
    Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  20. 100
    The scatterplot, linear regression equation, 95% confidence band, and <i>p</i>-value for the concentration of arsenic (As) in micrograms per liter (μg/L) versus oxidation-reduction potential (ORP) in millivolts (mV).

    The scatterplot, linear regression equation, 95% confidence band, and <i>p</i>-value for the concentration of arsenic (As) in micrograms per liter (μg/L) versus oxidation-reduction... by Seth H. Frisbie (7821866)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: